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Spheroid-type tumor cell cultureNovel spheroid-type tumor cell cultures directly isolated from patients’ tumors preserve tumor
characteristics better than traditionally grown cell lines. However, such cultures are not generally
used for high-throughput toxicity drug screens. In addition, the assays that are commonly used to
assess drug-induced toxicity in such screens usually measure a proxy for cell viability such as mito-
chondrial activity or ATP-content per culture well, rather than actual cell death. This generates con-
siderable assay-dependent differences in the measured toxicity values. To address this problem we
developed a robust method that documents drug-induced toxicity on a per-cell, rather than on a
per-well basis. The method involves automated drug dispensing followed by paired image- and
FACS-based analysis of cell death and cell cycle changes. We show that the two methods generate
toxicity data in 96-well format which are highly concordant. By contrast, the concordance of these
methods with frequently used well-based assays was generally poor. The reported method can be
implemented on standard automated microscopes and provides a low-cost approach for accurate
and reproducible high-throughput toxicity screens in spheroid type cell cultures. Furthermore,
the high versatility of both the imaging and FACS platforms allows straightforward adaptation of
the high-throughput experimental setup to include ﬂuorescence-based measurement of additional
cell biological parameters.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recently developed tissue culture protocols allow the genera-
tion of patient-derived cell lines from several tumor types in a
manner that preserves the genetic and phenotypic aspects of the
original tumor [1,2]. These culture protocols are therefore superior
over ‘traditional’ adherent culturing protocols [3,4]. It may be
expected that spheroid-type culture protocols will rapidly become
the standard in establishing and culturing human tumors from
diverse tissues. One obvious application of such cultures is to use
them in drug screens aimed at identifying effective drugs or drug
combinations for targeting speciﬁc tumor subtypes, or even indi-
vidual tumors, thus contributing to the personalization of cancer
care. However, this imposes an experimental challenge as tradi-
tional cytotoxicity assays have been developed and optimized for
traditional adherent cell culture models. High throughput toxicity
screens are usually based on plate-based proliferation or viability
assays [5]. The most commonly used approach is to measure the
per-well amount of some aspect of cellular metabolism or biomassas a proxy for the number of viable cells [6]. The principal methods
are (i) determination of ATP in cell lysates by luciferin/luciferase-
generated bioluminescence, (ii) reduction of tetrazolium salts such
as MTS and MTT to formazan by cellular dehydrogenases, and (iii)
determination of the total amount of nucleic acid per well by ﬂuo-
rescent DNA-binding cyanine dyes [7–10].
Importantly, these widely used methods can give highly vari-
able results for the same drug-cell line combination. Indeed, in
two large pharmacogenomic datasets (TCGA [11] and the Cancer
Cell line Encyclopedia [12]) the concordance of drug response data
for the same cell line was very poor. This was due to the different
platforms that were used to measure drug response, rather than to
differences in cell line identity or culture conditions [13,14].
We reasoned that toxicity assays in spheroid-type cultures
should ideally assess cell viability on a per-cell basis, rather than
an indirect measurement of ‘cellular activity’ per-well. Therefore,
we chose two highly versatile platforms based on imaging and
FACS, allowing well- and cell-based analysis of drug response. We
demonstrate that bothmethods produce highly concordant toxicity
values in drug-treated human spheroid cultures. Both methods use
widely available equipment and low-cost chemicals, yet produce
highly accurate and reproducible results in high-throughput
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discovery screens in spheroid-type tumor cultures.
2. Materials and methods
2.1. Cell culture
Patient-derived colonosphere lines were established as
described before [15]. The colonospheres are cultured in non-
adherent 10 cm dishes in Stem Cell Medium with 10 ng/mL b-
FGF (Abcam), which is refreshed twice a week. All cell culture
was carried out at 37 C in a 5% CO2 humidiﬁed incubator.
2.1.1. Generation of single cells
Colonospheres are spun down at 491g for 5 min and washed
twice with PBS, and are then incubated with 3 mL Accumax at
37 C for 3 min or until a suspension is formed. The suspension is
ﬁltered through a 40 lm cell strainer and the strainer is ﬂushed
with PBS. Take the single cells up in Stem Cell Medium in a
10 cm dish and add 10 ng/mL b-FGF. The cells are maintained in
a humidiﬁed 37 C incubator with 5% CO2 for 3–5 days to form
colonospheres.
2.2. Compound treatment
PSC-833 and irinotecan were obtained from commercial ven-
dors (Novartis, Basel, Switzerland and Campo; Pﬁzer, Capelle a/d
IJssel, The Netherlands). Three to ﬁve day old colonospheres were
ﬁltered with a 70 lm cell strainer and seeded in appropriate
density for each cell line in 150 lL Stem Cell Medium with
10 ng/mL b-FGF in 96-well plates. PSC-833 and irinotecan were
digitally dispensed with the HPD-300 (Hewlett Packard and
Tecan). Compounds were diluted in at least 75% DMSO before dig-
ital titration. Concentration series were 0–50 lg/mL for Irinotecan
and 0–4.5 lM for PSC-833 with a constant ratio of 2.5. In each well
normalization to 1% DMSO was performed by back ﬁlling with
100% DMSO again using the HPD-300. Colonospheres were incu-
bated in a humidiﬁed 37 C incubator with 5% CO2 for 1–4 days
with no further changes of media or re-addition of compounds.
2.3. Toxicity/proliferation assays
2.3.1. Image-based toxicity assay
To prevent the ﬂuorescent dyes from being pumped out of the
colonospheres by ATP binding cassette transporters [16,17], Verap-
amil 50 lMwas added to each well. Plates were placed in a humid-
iﬁed 37 C incubator with 5% CO2 for 30 min before adding the
ﬂuorescent dyes. Calcein Green AM 4 lM and Draq5™ 2 lM were
added to each well. Plates were placed in the incubator for
10 min prior to reading. The plate was spun down for 30 sec at
49 g and images were acquired on an ArrayScan VTi (Thermo Sci-
entiﬁc) at 5 magniﬁcation using a custom protocol (Supplemen-
tary Document 2). 12 images per well were made to visualize
whole wells. All DNA content was identiﬁed and visualized with
DRAQ5™. Live cells were identiﬁed with Calcein Green AM. The
intensity of the Calcein Green signal, per DRAQ5™ positive area
is calculated. The levels of intensity were normalized to and
expressed as a relative percentage of the plate-averaged vehicle
treated control.
2.3.2. Flow cytometry Nicoletti assay
Medium with the compounds was aspirated off and replaced
with 150 lL buffer, (PBS + 0,1% Triton-X + 0,1% sodium citrate, pH
7.4, supplemented with 50 lg/mL propidium iodide (PI)). Cells
were incubated overnight at 4 C [8]. Cell analysis was performeddirectly from the plate using the high-throughput sampler on a
3-laser Canto II ﬂow cytometer (Becton Dickinson, Mountain View,
CA). Fluorescent labeled beads (CS & T beads, Becton Dickinson,
Mountain View, CA) were used to standardize the ﬂow cytometer
and verify optical path and stream ﬂow. This procedure enables
controlled standardized results and allows the determination of
long-term drifts and incidental changes within the ﬂow cytometer.
No changes were observed which could affect the results. The PI
ﬂuorescence signal at FL2-A versus counts was used to determine
sub-G1 and cell cycle distribution. Levels of apoptosis were
normalized to and expressed as a relative percentage of the plate
averaged vehicle treated control.
2.3.3. CellTiter-Glo assay (Promega)
Measurements were made according to the manufacturer’s
protocol. Brieﬂy, plates were allowed to equilibrate at room tem-
perature for 30 min. Equal volumes of CellTiter-Glo reagents were
added directly to the wells. Plates were incubated at room temper-
ature for 10 min on a shaker and ﬂuorescence was measured on a
luminometer [7]. Luminescence reading was normalized to and
expressed as a relative percentage of the plate-averaged vehicle
treated control.
2.3.4. CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
(MTS) (Promega)
Measurements were made according to the manufacturer’s pro-
tocol. Brieﬂy, 20 lL of MTS reagent was added directly to the wells
and plates were incubated for 2 h in a humidiﬁed 37 C incubator
with 5% CO2. The plate was spun down and the supernatant trans-
ferred to a new plate. Absorbance was measured at 490 nm on a
96-well plate reader [18]. Absorbance was normalized to and
expressed as a relative percentage of the plate-averaged vehicle
treated control.
2.3.5. MultiTox-Fluor Multiplex Cytotoxicity Assay (Promega)
Measurements were made according to the manufacturer’s pro-
tocol. Brieﬂy, 20 lL of reagent was added directly to the wells and
plates were incubated for 1 h in a humidiﬁed 37 C incubator with
5% CO2. Fluorescence was measured on a 96-well plate reader at
excitation/emission 400/505 and 485/520 nm. Fluorescence read-
ing was normalized to and expressed as a relative percentage of
the plate-averaged vehicle treated control.
2.4. Statistical analysis
Differences per treatment group were calculated with an
unpaired t-test or an ANOVA, when appropriate. Correlations
between the assays were calculated via the Pearson’s test. Z-factors
were calculated to quantify the suitability of this assay as high-
throughput screen. Differences of repeated measurements with
different assays were calculated with the Friedman test. All statis-
tical tests were performed with GraphPad Prism software (Graph-
Pad, San Diego, CA). Differences with a P value of less than .05 were
considered statistically signiﬁcant.
3. Results
We have previously reported on the isolation and characteriza-
tion of a series of cancer stem cell (CSC)-enriched non-adherent
spheroid cultures from human colorectal tumors [15] While such
cultures are relatively resistant to oxaliplatin and 5-FU [19,20], they
are sensitive to irinotecan, provided that drug efﬂux is inhibited [15].
Here, we used irinotecan treatment of two phenotypically distinct
colonosphere cultures to develop a new toxicity assay for spher-
oid-type tumor cell cultures. CRC29 is relatively undifferentiated,
Fig. 1. Paired image- and FACS based toxicity assays. (A) Representative pictures, generated by the Thermo Scientiﬁc ArrayScan, of vehicle treated (upper panel) and
irinotecan-treated (50 lg/mL; lower panel) CRC29 colonospheres. DRAQ5 identiﬁes all live cells and cell fragments that are present in the wells. (B) Representative pictures of
vehicle-treated and irinotecan-treated (50 lg/mL; lower panel) CRC29 and CRC47 colonospheres stained with Calcein Green and DRAQ5. CRC47 colonospheres also received
PSC-833 (4 lM). CRC29 spheroids rapidly disintegrate following drug addition. CRC47 spheroids stay intact but gradually become smaller as the outer cells die and lose
Calcein ﬂuorescence. (C) The resolution of the ArrayScan camera allows analysis of single cells in high-throughput format. The DRAQ5 image shows chromatin condensation
of single drug-treated cells, characteristic of apoptosis. (D) Representative pictures of the FACS-based Nicoletti assay are shown for vehicle-treated (left panels) and
irinotecan-treated (right panels) CRC29 and CRC47 colonosphere lines. Drug treatment induces cell death which is measured as a peak of cell fragments with sub-G1 DNA
content. In addition, irinotecan induces a G1 arrest in CRC29 and a G2 arrest in CRC47 cells.
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Fig. 2. Correlation of image- and FACS-based toxicity assays. (A) IC50 curves generated on the imaging platform (left) on the FACS platform (right). Small uniform
colonospheres were treated for 72 or 48 h with concentration series of irinotecan (CRC29) or irinotecan and PSC-833 (CRC47). (B) Image based and FACS-generated data
points of the same sample series were plotted to calculate the concordance of the two assays. The correlation (r) values of the data points were calculated with the Pearson’s
test for each colonosphere line, p < 0.01.
88 K. Trumpi et al. / FEBS Open Bio 5 (2015) 85–90does not express drug efﬂux pumps, and is sensitive to irinotecan
monotherapy (Supplemental Fig. 1A and 1B). CRC47 iswell-differen-
tiated and expresses high levels of CK20 and ABCB1 (Supplemental
Fig. 1A and 1B). Therefore, CRC47 killing by irinotecan requires
ABCB1-mediated drug efﬂux inhibitionwith PSC-833 (Supplemental
Fig. 1C).
Equal numbers of small uniform colonospheres (CRC29, CRC47)
were plated in 96-well plates and were treated with a concentra-
tion series of irinotecan (0–50 lg/mL) in the absence or presence
of PSC833 respectively for 48–72 h. The drugs were added using a
robotic liquid handler (HPD300; Tecan). To identify all cells (liveand dead) the DNA was stained with DRAQ5™, a far-red emitting
ﬂuorescent DNA dye [21]. We chose this dye as its spectral proper-
ties do not interferewith those of commonly used anti-cancer drugs
or with Calcein-type live cell dyes. Furthermore, this DNA binding
dye is extremely photo stable compared to older generation DNA
dyes and it can be used in live cells [22]. Live cells were identiﬁed
by subsequent addition of Calcein Green AM [23,24]. The intensity
of Calcein ﬂuorescence per DRAQ5™ positive area was then mea-
sured. Analysis of the generated images showed that in both cell
lines the drug response was homogenous throughout the wells.
The DNA of single cells showed the condensed chromatin which
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Fig. 3. Concordance between toxicity assays. Tumor cells (CRC29, upper panel;
CRC47, lower panel) were treated with irinotecan (50 lg/mL). Drug-induced
toxicity was then simultaneously measured with 4 distinct assays (ArrayScan,
Multitox, MTS, Cell Titer Glo). The percentage of viable cells was then plotted as % of
control values.
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drug-induced cell death in spheroids starts in the outer cell layer.
These cells detach from the spheroid structure, ultimately leaving
a small proportion of live (Calcein-positive) cell clusters and single
cells (Fig. 1A and B). The percentage of drug-induced cell death,
based on the combined DRAQ5 and Calcein ﬂuorescence data was
then calculated and plotted relative to vehicle-treated control.
In parallel with the image based analyses an additional series of
similarly treated samples were analyzed for sub-G1 DNA content
(apoptosis) and cell cycle distribution [8]. To this end, the cells
were stained with propidium iodide and were analyzed on a 3-
laser Canto II ﬂow cytometer with a high-throughput sampler.
The generated DNA proﬁles clearly show irinotecan-induced cell
death. Notably, this was accompanied by a G1 arrest in one cell line
(CRC29) and by a G2 arrest in the other (CRC47; Fig. 1D).
Dose–response curves were generated for both assays (Fig. 2A).
Cross-comparison of the toxicity data revealed a very high and sig-
niﬁcant concordance of the results obtained on the two platforms
(Fig. 2B; Supplementary Table 1). Furthermore, the calculated
Z-factors of both cells lines, CRC29 0.78 and CRC47 0.68, show its
suitability as a method for high content screening.
Finally, we compared image based-generated toxicity values
with those generated by frequently used additional toxicity assays,
such as Cell Titer-Glo, Cell Titer 96 Aqueous Non-Radioactive Cell
Proliferation Assay and MultiTox-Fluor Multiplex Cytotoxicity
Assay. To this end, both cell lines were treated with irinotecan
(50 lg/mL; 48/72 h) and the percentage of viable cells was ana-
lyzed in parallel with all 4 assays. In both cell lines, the results from
all toxicity assays were signiﬁcantly different calculated via Fried-
man test, CRC29 p < 0.001 and CRC47 p = 0.003. When comparingeach assay to the image based toxicity assay via t-test, no signiﬁ-
cant differences were found between the Cell Titer Glo assay and
our novel image based assay. (Fig. 3). The toxicity values obtained
with the MTS and the multitox assay were signiﬁcantly different
and poor (p < 0.02).
4. Discussion
We present a robust method for high content screening of drug-
induced cell death in spheroid-type cultures, involving paired
imaging- and FACS-based analysis of cell viability and cell cycle
proﬁles. It provides a low-cost approach for accurate and reproduc-
ible high-throughput analysis of cell death and cell cycle arrest in
spheroid-type cell cultures. However, the method can also easily
be adapted for the study of many other aspects of spheroid biology,
by making use of the rapidly expanding toolbox of ﬂuorescent
reporters for cell biological parameters. Furthermore, the new gen-
eration of ArrayScan equipment allows three-dimensional imaging,
and this will greatly help in fully exploiting the beneﬁts of spher-
oid-type cell cultures.
We propose that cell-based assays such as the one presented in
this report can serve as an ideal screening method when perform-
ing toxicity screens. The only well-based viability assay that gener-
ated data that were signiﬁcantly concordant with that obtained
with the image based assay was the Cell-Titer-Glo assay which
measures ATP content per well (Promega). Cell-Titer-Glo may
therefore be considered as a good alternative for cell-based assays
in those experimental settings where only well-based viability
information is needed.
DRAQ5 is a relatively new DNA-binding dye in the far red
spectrum [22] comparable to Hoechst 33342 and with the same
efﬁcacy for staining live cells. Although Hoechst 33342 would have
been a more conservative choice, DRAQ5 is extremely photo stable,
is cell-permeant, and does not interfere with simultaneous imag-
ing of many widely used ﬂuorescent proteins (GFP, YFP, CFP, dsRed,
mCherry, Dendra2) and accurately reﬂects the spatial concentra-
tion of DNA in living cells.[25]. Furthermore, unlike Hoechst
33342 and Rhodamine123, it is not a substrate for ABC-trans-
porter-mediated efﬂux [26,27].
All materials used for the described methods are widely
available and relatively cheap. Furthermore, the assays are fast
and highly reproducible due to automated drug dispensing and a
protocol that does not involve washing steps. Therefore, the
described assay provides an ideal platform for testing large num-
bers of drugs in concentration series on patient-derived spher-
oid-type cell cultures. These features are extremely relevant and
valuable for the development of diagnostic protocols that are
aimed at personalizing cancer treatment.
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